首页|EBV-associated lymphoproliferative disease post-CAR-T cell therapy

EBV-associated lymphoproliferative disease post-CAR-T cell therapy

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Epstein-Barr virus(EBV)-associated lymphoproliferative diseases(EBV-LPDs)are common complications that occur after solid organ transplantation or allogeneic hematopoietic stem-cell transplantation(HSCT).However,their occurrence and treatment post-chimeric antigen receptor-modified T(CAR-T)cell therapy has not been reported.Two patients had been diagnosed with EBV-positive aggressive B-cell lymphoma and experienced relapses after multiple lines of treatment.After receiving CAR-T cell therapy in tandem with autologous HSCT,the patients achieved complete remission.However,with a median time of 38.5 months after CAR-T cell therapy,B-cell-derived EBV-LPDs were diagnosed,and they were relieved through the administration of immune checkpoint inhibitor or B-cell-depleting agents.Collectively,our report suggests that EBV-LPDs may represent a long-term adverse event after CAR-T cell therapy,especially in patients who previously had EBV-positive disorders,and they can be resolved by immune normalization strategy or B-cell depleting therapy.

EBV-associated lymphoproliferative diseasechimeric antigen receptor T-cellautologous stem cell transplantationimmune checkpoint inhibitor

Shiyuan Zhang、Xiaoxi Zhou、Shangkun Zhang、Na Wang、Tongcun Zhang、Donghua Zhang、Qilin Ao、Yang Cao、Liang Huang

展开 >

Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

Immunotherapy Research Center for Hematologic Diseases of Hubei Province,Wuhan 430030,China

Institute of Biology and Medicine,College of Life and Health Sciences,Wuhan University of Science and Technology,Wuhan 430081,China

Department of Pathology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College,Tianjin 300020,China

Tianjin Institute

展开 >

国家自然科学基金国家重点研发计划

820702112022YFC2502604

2024

10.1007/s11684-023-1032-8

医学前沿
高等教育出版社

医学前沿

CSTPCD
影响因子：1.362
ISSN：2095-0217
年,卷(期)：2024.18(2)
  • 12